Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine , University of Belgrade , Belgrade , Serbia.
School of Medicine , University of Belgrade , Belgrade , Serbia.
J Virus Erad. 2016 Jan 1;2(1):32-5. doi: 10.1016/S2055-6640(20)30690-7.
Access to combination antiretroviral treatment (cART) and toxicity profiles of antiretroviral medications have significantly improved during the last three decades. In order to optimise treatment outcomes, achieve favourable virological suppression and immunological status, balanced with potential adverse effects of cART, it is considered beneficial to maintain first-line antiretroviral treatment for as long as possible. However, the Republic of Serbia, as a resource-limited setting, often experiences interruptions to drug supplies. Data are very limited in Serbia concerning the initial antiretroviral regimens prescribed and the reasons for treatment changes.
The aim of this study was to determine the most frequently prescribed antiretroviral drugs within first-line cART regimens in drug-naïve patients in Serbia and the reasons for switching drugs.
All HIV-infected individuals who started cART at the HIV/AIDS Center of Infectious and Tropical Diseases, Clinical Centre of Serbia, from 1 January 2004 until 1 July 2014 were included. A cohort of 339 patients were retrospectively analysed to review their initial treatment regimens. All analyses were performed using the SPSS statistical package version 11.0. Descriptive measurements and Kaplan-Meier survival curves were used.
The most frequently prescribed nucleoside reverse transcriptase inhibitor (NRTI) backbones in the cART regiment were fixed combinations of abacavir and lamivudine (n=181, 53.3%) and of zidovudine and lamivudine (n=103, 30.5%). Efavirenz was the most commonly prescribed 'third' drug (n=254, 75%). Where given, reasons for switching initial cART were shortage of antiretroviral drugs (e.g. out of stock, n=53, 37.6%), toxicity (n=49, 34.3%), physician choice (n=21, 14.6%), resistance (n=15, 10.6%), and patient choice (n=4, 2.9%). Mean duration of first-line cART was 20±17 months.
The most frequently prescribed initial cART regimen in Serbia is not the preferred first choice, but an alternative option according to the international antiretroviral treatment guidelines. Duration of first-line cART is short and a switch to second-line cART is often made due to a shortage of antiretroviral medications and the more severe side effects resulting from the use of older drugs.
在过去的三十年中,人们获得了联合抗逆转录病毒治疗(cART),并且抗逆转录病毒药物的毒性特征也得到了显著改善。为了优化治疗效果,实现有利的病毒学抑制和免疫状态,同时平衡 cART 的潜在不良反应,人们认为尽可能长时间地维持一线抗逆转录病毒治疗是有益的。然而,塞尔维亚共和国作为一个资源有限的国家,经常面临药物供应中断的情况。在塞尔维亚,关于最初规定的抗逆转录病毒治疗方案以及治疗方案改变的原因的数据非常有限。
本研究旨在确定在塞尔维亚接受一线 cART 治疗的初治患者中最常开的抗逆转录病毒药物,并确定药物更换的原因。
从 2004 年 1 月 1 日至 2014 年 7 月 1 日,所有在传染病和热带病感染 HIV/AIDS 中心开始 cART 的 HIV 感染者均被纳入研究。回顾性分析了 339 例患者的初始治疗方案。所有分析均使用 SPSS 统计软件包第 11.0 版进行。使用描述性测量和 Kaplan-Meier 生存曲线进行分析。
cART 方案中最常开的核苷逆转录酶抑制剂(NRTI)骨干药物是阿巴卡韦和拉米夫定(n=181,53.3%)以及齐多夫定和拉米夫定(n=103,30.5%)的固定组合。依非韦伦(efavirenz)是最常开的“第三种”药物(n=254,75%)。改变初始 cART 的原因包括抗逆转录病毒药物短缺(如缺货,n=53,37.6%)、毒性(n=49,34.3%)、医生选择(n=21,14.6%)、耐药性(n=15,10.6%)和患者选择(n=4,2.9%)。一线 cART 的平均持续时间为 20±17 个月。
塞尔维亚最常开的初始 cART 方案不是首选方案,而是根据国际抗逆转录病毒治疗指南的替代方案。一线 cART 的持续时间很短,由于抗逆转录病毒药物短缺以及使用较老药物导致的更严重副作用,经常切换到二线 cART。